Skip to main content
. 2022 May 16;5(5):e2212327. doi: 10.1001/jamanetworkopen.2022.12327

Figure 2. Percentage of Individuals Who Discontinued Oncology Drugs Because of Adverse Events and Withdrawal in the Adjuvant vs Metastatic Settings by Drug and Indication.

Figure 2.

HNSCC indicates head and neck squamous cell carcinoma; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma; SCLC, small cell lung cancer.